Related Experiment Video

Updated: Jul 19, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

Chagas' disease and the use of implantable cardioverter-defibrillators in Brazil

Ronaldo F Rosa1, Argemiro S Neto, Roberto A Franken

  • 1Geriatric Cardiology Department, Brazilian Cardiology Society and Santa Casa Hospital, Rua Dias Leme 11, CEP 03118-040 São Paulo, SP, Brazil. dr.ronaldo@terra.com.br

The American Journal of Geriatric Cardiology
|November 7, 2006
PubMed

Insights

Chagas' disease management in Brazil is evolving. Certain patients with low ejection fraction may benefit from cardioverter-defibrillator therapy and resynchronization, guided by electrophysiologic studies.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Epidemiology

Background:

  • Chagas' disease poses significant cardiovascular risks in Brazil.
  • Low ejection fraction is a common complication, necessitating advanced treatment strategies.

Purpose of the Study:

  • To review the epidemiology and pathogenesis of Chagas' disease in Brazil.
  • To evaluate the role of cardioverter-defibrillator therapy in affected patients.
  • To explore the benefits of resynchronization therapy in conjunction with cardioverter-defibrillators.

Main Methods:

  • Review of epidemiological and etiological data for Chagas' disease in Brazil.
  • Analysis of treatment outcomes for patients with low ejection fraction.
  • Discussion of electrophysiologic study utility for device selection.

Main Results:

  • Cardioverter-defibrillator treatment can be beneficial for select Chagas' disease patients with low ejection fraction.
  • Resynchronization therapy may enhance outcomes when combined with cardioverter-defibrillator implantation.
  • Electrophysiologic studies aid in determining the suitability of implantable cardioverter-defibrillators.

Conclusions:

  • Integrated treatment approaches are crucial for managing cardiovascular complications of Chagas' disease.
  • Implantable cardioverter-defibrillators and resynchronization therapy represent important therapeutic options.
  • Electrophysiologic assessment is key for personalized treatment strategies in Chagas' cardiomyopathy.

More Related Videos

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies07:59

Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies

Published on: May 31, 2024

Related Concept Videos

American Trypanosomiasis01:22

American Trypanosomiasis

Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...